Tretazicar

Identification

Name
Tretazicar
Accession Number
DB04253  (EXPT00837, DB12772)
Type
Small Molecule
Groups
Investigational
Description

Tretazicar is under investigation in clinical trial NCT00746590 (Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma).

Structure
Thumb
Synonyms
Not Available
External IDs
CB-1954 / CB1954 / NSC-115829
Categories
UNII
7865D5D01M
CAS number
21919-05-1
Weight
Average: 252.1836
Monoisotopic: 252.049469386
Chemical Formula
C9H8N4O5
InChI Key
WOCXQMCIOTUMJV-UHFFFAOYSA-N
InChI
InChI=1S/C9H8N4O5/c10-9(14)5-3-7(11-1-2-11)8(13(17)18)4-6(5)12(15)16/h3-4H,1-2H2,(H2,10,14)
IUPAC Name
5-(aziridin-1-yl)-2,4-dinitrobenzamide
SMILES
NC(=O)C1=CC(N2CC2)=C(C=C1[N+]([O-])=O)[N+]([O-])=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UOxygen-insensitive NAD(P)H nitroreductaseNot AvailableEscherichia coli (strain K12)
URibosyldihydronicotinamide dehydrogenase [quinone]Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Tretazicar.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Tretazicar.Experimental
BevacizumabBevacizumab may increase the cardiotoxic activities of Tretazicar.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Tretazicar.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Tretazicar.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Tretazicar.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Tretazicar.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Tretazicar.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Tretazicar.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tretazicar.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Tretazicar.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Tretazicar.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Tretazicar.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Tretazicar.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Tretazicar.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Tretazicar.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Tretazicar.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Tretazicar.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Tretazicar.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
89105
PubChem Substance
46509068
ChemSpider
80403
BindingDB
50004681
ChEMBL
CHEMBL23330
HET
CB1
PDB Entries
1idt / 1xi2 / 1zx1 / 2bzs

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.904 mg/mLALOGPS
logP0.04ALOGPS
logP0.64ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)11.29ChemAxon
pKa (Strongest Basic)-2.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area137.74 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity62.25 m3·mol-1ChemAxon
Polarizability21.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9849
Blood Brain Barrier+0.9518
Caco-2 permeable-0.5201
P-glycoprotein substrateNon-substrate0.6154
P-glycoprotein inhibitor INon-inhibitor0.938
P-glycoprotein inhibitor IINon-inhibitor0.9581
Renal organic cation transporterNon-inhibitor0.9005
CYP450 2C9 substrateNon-substrate0.8779
CYP450 2D6 substrateNon-substrate0.8267
CYP450 3A4 substrateNon-substrate0.527
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.6828
BiodegradationNot ready biodegradable0.6136
Rat acute toxicity2.4518 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9656
hERG inhibition (predictor II)Non-inhibitor0.8456
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dinitroanilines. These are organic compounds containing an aniline moiety, which is substituted at 2 positions by a nitro group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Aniline and substituted anilines
Direct Parent
Dinitroanilines
Alternative Parents
Aminobenzamides / Benzamides / Phenylaziridines / Indoles / Nitrobenzenes / Benzoyl derivatives / Dialkylarylamines / Nitroaromatic compounds / Amino acids and derivatives / Primary carboxylic acid amides
show 8 more
Substituents
Dinitroaniline / Aminobenzamide / Aminobenzoic acid or derivatives / Benzamide / Benzoic acid or derivatives / Indole / Nitrobenzene / Phenylaziridine / Nitroaromatic compound / Benzoyl
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Unknown
General Function
Nad(p)h nitroreductase activity
Specific Function
Reduction of a variety of nitroaromatic compounds using NADH (and to lesser extent NADPH) as source of reducing equivalents; two electrons are transferred. Capable of reducing nitrofurazone, quinon...
Gene Name
nfsB
Uniprot ID
P38489
Uniprot Name
Oxygen-insensitive NAD(P)H nitroreductase
Molecular Weight
23904.99 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nadph dehydrogenase (quinone) activity
Specific Function
The enzyme apparently serves as a quinone reductase in connection with conjugation reactions of hydroquinones involved in detoxification pathways as well as in biosynthetic processes such as the vi...
Gene Name
NQO2
Uniprot ID
P16083
Uniprot Name
Ribosyldihydronicotinamide dehydrogenase [quinone]
Molecular Weight
25918.4 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:39